Fisher & Paykel Healthcare (ASX:FPH) Growth Rank: 7 (As of Jul. 30, 2026) — 30% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:FPH Fisher & Paykel Healthcare Corp Ltd ASX:FPH
88 GF Score
Price A$34.24
GF Value A$36.72
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare Growth Rank?

Fisher & Paykel Healthcare ASX:FPH -1.24% 88 Growth Rank is 7 as of Jul. 30, 2026, which is 30% below its 10-year median of 10.00. GuruFocus rates ASX:FPH with a GF Score™ of 88/100 and a GF Value™ of A$36.72 (Fairly Valued). The stock has 2 warning signs investors should review.

Fisher & Paykel Healthcare has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Fisher & Paykel Healthcare Growth Rank Related Terms

ASX:FPH vs ISRG, BDX, MDLN: Growth Rank Comparison

For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fisher & Paykel Healthcare Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Growth Rank distribution charts can be found below:

* The bar in red indicates where Fisher & Paykel Healthcare's Growth Rank falls into.


ASX:FPH
88GF Score
Fisher & Paykel Healthcare Corp Ltd ASX:FPH
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Fisher & Paykel Healthcare (ASX:FPH) has a Growth Rank of 7 as of Jul. 30, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Fisher & Paykel Healthcare and its competitors. This is 30% below median its historical median of 10.00. Over the past decade, Fisher & Paykel Healthcare's Growth Rank has ranged from 6.00 to 10.00.
Is Fisher & Paykel Healthcare's Growth Rank too high?
Fisher & Paykel Healthcare's current Growth Rank of 7 is 30% below median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 10.00. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Growth Rank compare to ISRG and BDX?
Fisher & Paykel Healthcare's Growth Rank of 7 can be compared against companies in the Medical Devices & Instruments industry. Historically, Fisher & Paykel Healthcare's own Growth Rank has ranged from 6.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Fisher & Paykel Healthcare and its competitors. Fisher & Paykel Healthcare's current Growth Rank is 7, which is 30% below median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.72, compared to a current price of A$34.24 — trading 6.8% below its estimated fair value. The current Growth Rank is 7, which is 30% below median its 10-year median of 10.00. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Growth Rank is 7 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of A$34.24 is trading 6.8% below its estimated GF Value™ of A$36.72. GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.

Key valuation signals for ASX:FPH:

  • Growth Rank: 7 (30% below median its 10-year median of 10.00)
  • GF Value™: A$36.72 vs. price of A$34.24 (6.8% below fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fisher & Paykel Healthcare Business Description

Other Exchanges FSPKF:USAFPH:New Zealand
Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score

Get the complete analysis for ASX:FPH

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$34.24
Price
A$36.72
GF Value